Pregled bibliografske jedinice broj: 899139
Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study
Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study // The American Journal of the Medical Sciences, 354 (2017), 6; 553-560 doi:10.1016/j.amjms.2017.07.005 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 899139 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study
Autori
Gobić, David ; Tomulić, Vjekoslav ; Lulić, Davorka ; Židan, David ; Brusich, Sandro ; Jakljević, Tomislav ; Zaputović, Luka
Izvornik
The American Journal of the Medical Sciences (0002-9629) 354
(2017), 6;
553-560
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Angioplasty, Coronary ; Balloon dilation ; Drug-eluting stents ; Myocardial infarction ; Percutaneous coronary intervention
Sažetak
Drug-eluting stents (DES) represent a significant evolution in the treatment of patients with acute myocardial infarction with ST elevation. However, stent-related adverse events have led to an introduction of drug-coated balloons (DCB) applied particularly to bifurcation lesions, in-stent restenosis and small vessel disease. The aim of this study was to determine whether DCB-only strategy has a similar safety profile and equal angiographic and clinical outcomes to DES implantation in primary percutaneous coronary intervention (pPCI). Seventy-five STEMI patients were randomized into DES and DCB groups of 37 and 38 patients, respectively. The study end-points were major adverse cardiac events and the late lumen loss during the 6 months following the pPCI. Reinfarction occurred in 5.4% of patients in the DES and 5.3% of patients in the DCB group after 1 month (risk ratio = 1.03, 95% CI [0.15-6.91], P = 0.98). After 6 months, major adverse cardiac events were reported in 5.4% of patients in the DES group and none in the DCB group (risk ratio = 5.13, 95% CI [0.25-103.42], P = 0.29). Late lumen loss in the DES group was 0.10 ± 0.19 mm and −0.09 ± 0.09 mm in the DCB group (P < 0.05). A DCB-only strategy is safe and feasible in the pPCI setting, and showed good clinical and angiographic outcomes in 6 months follow-up period.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Luka Zaputović
(autor)
David Gobić
(autor)
Vjekoslav Tomulić
(autor)
Sandro Brusich
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE